Table 2.

In-progress Studies of CMR for SCD Risk Stratification

Study title	Number of patients and sites	Patient cohort	Study Design	CMR metrics	Follow-up
HCMR72	n=2750 44 international sites	Established or new HCM diagnosis 18–65 years old	Prospective observational registry	LV and RV volumes and function LV and RV mass Hypertrophy LGE T1 for diffuse fibrosis	5 years for composite endpoint: cardiac death aborted SCD need for heart transplant
PROTECT-ICD Trial73	n=1058, 400 with CMR 25–30 international sites	2–40 days after first or repeat acute MI with LVEF ≤ 40%	RCT with randomization to electrophysiology study-guided ICD Secondary aim to relate CMR with electrophysiology study results and outcomes	LV size LV function Myocardial edema Infarct size Peri-infarct injury T1 times and ECV	2 years for combined endpoint of Non-fatal ventricular arrhythmia SCD
CMR-GUIDE74	n=949 23 sites in Australia and Europe	LVEF 36–50% due to coronary artery disease or NICM	RCT with randomization to ICD or ILR in those with scar by CMR-LGE	LV volumes and function LV mass T1 mapping Infarct size	3 years for composite of SCD Ventricular arrhythmia
PROSe-ICD Extension www.clinicaltrials.gov, NCT00733590	n=600 3 US sites	ICM or NICM undergoing first ICD pulse generator change	Prospective observational registry	LV and RV volumes and function LV mass Extent of scar and scar heterogeneity	5 years for appropriate ICD firing or SCD

HCMR = Hypertrophic Cardiomyopathy Registry

PROTECT-ICD = Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction

LV = left ventricle

RV = right ventricle

RCT = randomized control trial

ECV = extracellular volume

CMR-GUIDE = Cardiovascular Magnetic Resonance GUIDEd management of mild-moderate LV systolic dysfunction

ILR = implantable loop recorder

PROSe-ICD = Prospective Observational Study of the ICD in Sudden Cardiac Death Prevention